Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$105.66
0.910.87%
al cierre: -
$105.66
0.000.00%
After hour: 4:00 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
BioNTech SE ha un obiettivo di prezzo di consenso pari a $137.39, stabilito in base alle ultime valutazioni degli analisti di 20. Le ultime 3 valutazioni degli analisti sono state rilasciate da JP Morgan, Morgan Stanley y JP Morgan il octubre 23, 2025, octubre 10, 2025 y septiembre 22, 2025. Con un obiettivo di prezzo medio di $124 tra le JP Morgan, Morgan Stanley y JP Morgan, c'è un implicito 17.36% upside per BioNTech SE da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
JP Morgan
Morgan Stanley
HC Wainwright & Co.
Wells Fargo
B of A Securities
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para BioNTech
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/23/2025 | 13.57% | JP Morgan | $121 → $120 | Maintains | Neutral | |||
10/10/2025 | 23.98% | Morgan Stanley | $133 → $131 | Maintains | Overweight | |||
09/22/2025 | 14.52% | JP Morgan | $116 → $121 | Maintains | Neutral | |||
09/08/2025 | 28.71% | HC Wainwright & Co. | $136 → $136 | Reiterates | Buy → Buy | |||
08/14/2025 | 28.71% | HC Wainwright & Co. | $138 → $136 | Maintains | Buy | |||
08/05/2025 | 41.96% | Wells Fargo | $170 → $150 | Maintains | Overweight | |||
08/05/2025 | 26.82% | B of A Securities | $126 → $134 | Maintains | Buy | |||
07/16/2025 | 19.25% | B of A Securities | $127 → $126 | Maintains | Buy | |||
07/10/2025 | 25.88% | Morgan Stanley | $132 → $133 | Maintains | Overweight | |||
06/25/2025 | 30.61% | HC Wainwright & Co. | $138 → $138 | Reiterates | Buy → Buy | |||
06/16/2025 | 30.61% | HC Wainwright & Co. | $145 → $138 | Maintains | Buy | |||
06/05/2025 | 37.23% | HC Wainwright & Co. | $134 → $145 | Maintains | Buy | |||
06/03/2025 | 46.7% | Truist Securities | $151 → $155 | Reiterates | Buy → Buy | |||
05/29/2025 | 4.11% | Goldman Sachs | → $110 | Initiates | → Neutral | |||
05/22/2025 | 9.79% | JP Morgan | $120 → $116 | Maintains | Neutral | |||
05/22/2025 | 26.82% | HC Wainwright & Co. | $134 → $134 | Reiterates | Buy → Buy | |||
05/14/2025 | 26.82% | HC Wainwright & Co. | $145 → $134 | Maintains | Buy | |||
05/06/2025 | 32.5% | Citigroup | $145 → $140 | Maintains | Buy | |||
05/06/2025 | 24.93% | Morgan Stanley | $140 → $132 | Maintains | Overweight | |||
04/01/2025 | 37.23% | HC Wainwright & Co. | $150 → $145 | Maintains | Buy | |||
03/13/2025 | 37.23% | Citigroup | → $145 | Initiates | → Buy | |||
03/11/2025 | 42.91% | Truist Securities | $172 → $151 | Maintains | Buy | |||
03/11/2025 | 31.55% | Morgan Stanley | $145 → $139 | Maintains | Overweight | |||
03/11/2025 | 62.26% | Canaccord Genuity | $171.44 → $171.44 | Maintains | Buy | |||
03/11/2025 | 35.34% | BMO Capital | $130 → $143 | Maintains | Outperform | |||
01/27/2025 | 13.57% | JP Morgan | $122 → $120 | Maintains | Neutral | |||
01/10/2025 | 62.79% | Truist Securities | → $172 | Initiates | → Buy | |||
12/11/2024 | 60.89% | Wells Fargo | → $170 | Initiates | → Overweight | |||
11/27/2024 | 62.26% | Canaccord Genuity | $171 → $171.44 | Maintains | Buy | |||
11/26/2024 | 15.46% | JP Morgan | $124 → $122 | Maintains | Neutral | |||
11/19/2024 | 18.3% | Evercore ISI Group | $110 → $125 | Upgrade | In-Line → Outperform | |||
11/18/2024 | 61.84% | Canaccord Genuity | $171 → $171 | Maintains | Buy | |||
11/18/2024 | 41.96% | HC Wainwright & Co. | $150 → $150 | Reiterates | Buy → Buy | |||
11/14/2024 | 61.84% | Canaccord Genuity | $171 → $171 | Maintains | Buy | |||
11/08/2024 | 29.66% | Goldman Sachs | $90 → $137 | Upgrade | Neutral → Buy | |||
11/06/2024 | 15.46% | TD Cowen | $132 → $122 | Maintains | Hold | |||
11/05/2024 | 15.46% | TD Cowen | $132 → $122 | Maintains | Hold | |||
11/04/2024 | 17.36% | JP Morgan | $125 → $124 | Maintains | Neutral | |||
10/07/2024 | 28.71% | HSBC | $97 → $136 | Maintains | Buy | |||
10/07/2024 | 41.96% | HC Wainwright & Co. | $113 → $150 | Maintains | Buy | |||
09/24/2024 | 37.23% | Morgan Stanley | $93 → $145 | Upgrade | Equal-Weight → Overweight | |||
09/19/2024 | 41.96% | Deutsche Bank | $95 → $150 | Maintains | Buy | |||
09/18/2024 | 23.98% | UBS | $97 → $131 | Maintains | Neutral | |||
09/17/2024 | 41.96% | Jefferies | $96 → $150 | Upgrade | Hold → Buy | |||
09/16/2024 | 18.3% | JP Morgan | $91 → $125 | Upgrade | Underweight → Neutral | |||
09/16/2024 | 41.96% | B of A Securities | $125 → $150 | Maintains | Buy | |||
09/16/2024 | 6.95% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
09/13/2024 | -9.14% | Jefferies | $90 → $96 | Maintains | Hold | |||
08/27/2024 | 6.95% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
08/19/2024 | 6.95% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
08/15/2024 | -13.87% | JP Morgan | $94 → $91 | Maintains | Underweight | |||
08/07/2024 | -10.09% | Deutsche Bank | $95 → $95 | Upgrade | Hold → Buy | |||
08/06/2024 | -19.55% | TD Cowen | $98 → $85 | Maintains | Hold | |||
08/01/2024 | 6.95% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
06/26/2024 | 6.95% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
06/12/2024 | -11.04% | JP Morgan | $90 → $94 | Maintains | Underweight | |||
06/10/2024 | 6.95% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
06/04/2024 | 6.95% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
06/03/2024 | 6.95% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
05/30/2024 | 6.95% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
05/28/2024 | 6.95% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
05/24/2024 | 6.95% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
05/14/2024 | -5.36% | Evercore ISI Group | → $100 | Initiates | → In-Line | |||
05/08/2024 | 6.95% | HC Wainwright & Co. | $107 → $113 | Maintains | Buy | |||
05/07/2024 | -7.25% | TD Cowen | $95 → $98 | Maintains | Hold | |||
05/07/2024 | 15.46% | BMO Capital | $123 → $122 | Maintains | Outperform | |||
04/17/2024 | 1.27% | HC Wainwright & Co. | $107 → $107 | Reiterates | Buy → Buy | |||
03/27/2024 | -4.41% | UBS | $110 → $101 | Maintains | Neutral | |||
03/22/2024 | -14.82% | JP Morgan | $99 → $90 | Maintains | Underweight | |||
03/21/2024 | 61.84% | Canaccord Genuity | $171 → $171 | Reiterates | Buy → Buy | |||
03/21/2024 | 16.41% | BMO Capital | $127 → $123 | Maintains | Outperform | |||
02/28/2024 | -5.36% | Goldman Sachs | $113 → $100 | Maintains | Neutral | |||
02/23/2024 | 61.84% | Canaccord Genuity | $171 → $171 | Reiterates | Buy → Buy | |||
02/23/2024 | 20.2% | BMO Capital | → $127 | Initiates | → Outperform | |||
02/21/2024 | 61.84% | Canaccord Genuity | $171 → $171 | Reiterates | Buy → Buy | |||
02/20/2024 | 61.84% | Canaccord Genuity | $168 → $171 | Maintains | Buy | |||
01/23/2024 | 1.27% | HC Wainwright & Co. | $133 → $107 | Maintains | Buy | |||
12/01/2023 | -6.3% | JP Morgan | $106 → $99 | Downgrade | Neutral → Underweight | |||
11/27/2023 | 25.88% | HC Wainwright & Co. | → $133 | Reiterates | Buy → Buy | |||
11/14/2023 | 25.88% | HC Wainwright & Co. | $180 → $133 | Maintains | Buy | |||
11/08/2023 | 5.05% | Morgan Stanley | $110 → $111 | Maintains | Equal-Weight | |||
10/17/2023 | 4.11% | Morgan Stanley | $116 → $110 | Maintains | Equal-Weight | |||
10/16/2023 | 5.05% | HSBC | $124 → $111 | Downgrade | Buy → Hold | |||
08/28/2023 | 70.36% | HC Wainwright & Co. | → $180 | Reiterates | Buy → Buy | |||
08/10/2023 | 70.36% | HC Wainwright & Co. | $181 → $180 | Maintains | Buy | |||
08/08/2023 | 9.79% | Morgan Stanley | $119 → $116 | Maintains | Equal-Weight | |||
08/01/2023 | 12.63% | Morgan Stanley | $119 → $119 | Reiterates | Equal-Weight → Equal-Weight | |||
07/31/2023 | 12.63% | Morgan Stanley | $119 → $119 | Reiterates | Equal-Weight → Equal-Weight | |||
07/24/2023 | 12.63% | Morgan Stanley | $119 → $119 | Reiterates | Equal-Weight → Equal-Weight | |||
07/17/2023 | 12.63% | Morgan Stanley | $119 → $119 | Reiterates | Equal-Weight → Equal-Weight | |||
07/14/2023 | 17.36% | HSBC | → $124 | Initiates | → Buy | |||
07/11/2023 | 12.63% | Morgan Stanley | $124 → $119 | Maintains | Equal-Weight | |||
06/26/2023 | 17.36% | Morgan Stanley | $124 → $124 | Reiterates | Equal-Weight → Equal-Weight | |||
06/20/2023 | 17.36% | Morgan Stanley | → $124 | Reiterates | Equal-Weight → Equal-Weight | |||
06/16/2023 | 92.13% | Canaccord Genuity | $203 → $203 | Reiterates | Buy → Buy | |||
06/12/2023 | 17.36% | Morgan Stanley | → $124 | Reiterates | → Equal-Weight | |||
06/09/2023 | 71.3% | HC Wainwright & Co. | → $181 | Reiterates | → Buy | |||
06/01/2023 | 71.3% | HC Wainwright & Co. | $198 → $181 | Maintains | Buy | |||
05/23/2023 | 87.39% | HC Wainwright & Co. | $210 → $198 | Maintains | Buy | |||
05/18/2023 | 13.57% | Deutsche Bank | $135 → $120 | Maintains | Hold |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de BioNTech (BNTX)?
El último precio objetivo de BioNTech (NASDAQ:BNTX) fue comunicado por JP Morgan el octubre 23, 2025. La firma de analistas fijó un precio objetivo para $120.00 que espera BNTX a rise dentro de 12 meses (un posible 13.57% upside). 38 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre BioNTech (BNTX)?
La última calificación de analistas para BioNTech (NASDAQ:BNTX) fue proporcionada por JP Morgan, y BioNTech mantuvo su neutral calificación.
¿Cuándo se produjo la última revisión al alza de BioNTech (BNTX)?
La última revisión al alza de BioNTech SE se produjo en noviembre 19, 2024, cuando Evercore ISI Group elevó su precio objetivo a $125. Evercore ISI Group anteriormente tenía an in-line para BioNTech SE.
¿Cuándo fue la última revisión a la baja de BioNTech (BNTX)?
La última revisión a la baja de BioNTech SE se produjo en diciembre 1, 2023, cuando JP Morgan cambió su precio objetivo de $106 a $99 para BioNTech SE.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para BioNTech (BNTX)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de BioNTech, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de BioNTech se registró el octubre 23, 2025, por lo que la próxima calificación estará disponible en torno al octubre 23, 2026.
¿Es correcta la calificación de los analistas sobre BioNTech (BNTX)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de BioNTech (BNTX) fue un mantuvo con un precio objetivo de $121.00 a $120.00. El precio actual al que cotiza BioNTech (BNTX) es de $105.66, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.